Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AdCOVID

Vaccine (Adenoviral vector) · Immune activation · developed by Altimmune

Phase 1 Most advanced trial (none active)
ALT Developer
1 Registered trials

What is AdCOVID?

AdCOVID is an investigational vaccine studied in Healthy Volunteers.

At a glance

Drug type
Vaccine (Adenoviral vector)
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
Altimmune, Inc. (ALT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04679909 Phase 1 Healthy Volunteers Completed ALT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from Altimmune

FP-02.2 Vaccine Phase 1 HepTcell Phase 2 NasoShield Phase 1 NasoVAX Phase 2 Pemvidutide Phase 3

Follow ALT, the company behind AdCOVID

See ALT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.